Tomas Vanasek
Hradec Kralove, KR, Czech Republic
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 13 publications
Persistence of advanced therapies in patients with ulcerative colitis: real-world data from the nationwide CREdIT registry.
Journal: Therapeutic advances in gastroenterology
Published: November 18, 2025
Clinical Trial: A Pragmatic Randomised Controlled Study to Assess the Effectiveness of Two Patient Management Strategies in Mild to Moderate Ulcerative Colitis-The OPTIMISE Study.
Journal: Journal of clinical medicine
Published: July 24, 2024
Mucosal healing is not associated with better outcome during 7 years of follow-up in pediatric patients with Crohn's disease.
Journal: Minerva pediatrics
Published: April 13, 2021
Long-term Safety and Efficacy of the Anti-MAdCAM-1 Monoclonal Antibody Ontamalimab [SHP647] for the Treatment of Ulcerative Colitis: The Open-label Study TURANDOT II.
Journal: Journal of Crohn's & colitis
Published: February 18, 2021
Chronic cholestatic liver diseases - Primary biliary cholangitis and Primary sclerosing cholangitis.
Chronic cholestatic liver diseases - Primary biliary cholangitis and Primary sclerosing cholangitis.
Journal: Vnitrni lekarstvi
Published: September 18, 2020
A Global, Prospective, Observational Study Measuring Disease Burden and Suffering in Patients with Ulcerative Colitis Using the Pictorial Representation of Illness and Self-Measure Tool.
Journal: Journal of Crohn's & colitis
Published: May 15, 2020
Effect of tight control management on Crohn's disease (CALM): a multicentre, randomised, controlled phase 3 trial.
Journal: Lancet (London, England)
Published: August 15, 2017
Anti-MAdCAM antibody (PF-00547659) for ulcerative colitis (TURANDOT): a phase 2, randomised, double-blind, placebo-controlled trial.
Journal: Lancet (London, England)
Published: December 07, 2016
Clinical monitoring: infliximab biosimilar CT-P13 in the treatment of Crohn's disease and ulcerative colitis.
Journal: Scandinavian journal of gastroenterology
Published: March 23, 2016
A randomized controlled trial of the efficacy and safety of CCX282-B, an orally-administered blocker of chemokine receptor CCR9, for patients with Crohn's disease.
Journal: PloS one
Published: October 25, 2012
Last Updated: 09/26/2026